IL-36 Staining Distinguishes Clear Cell Acanthoma From Psoriasis
- 6 June 2024
- journal article
- letter
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 46 (8) , 549-551
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- IL‐36α and IL‐36γ expressions in the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema: A retrospective histopathologic and immunohistochemical studyJournal of Cutaneous Pathology, 2021
- Interleukin 36 expression in psoriasis variants and other dermatologic diseases with psoriasis‐like histopathologic featuresJournal of Cutaneous Pathology, 2021
- Clear Cell Acanthoma: A Review of Clinical and Histologic VariantsDermatopathology, 2020
- Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor–associated dermatitisJournal of the American Academy of Dermatology, 2020
- The Significance of IL-36 Hyperactivation and IL-36R Targeting in PsoriasisInternational Journal of Molecular Sciences, 2019
- Clear cell acanthoma (CCA)-like lesions of the nipple/areola: A clinicopathological study of 12 cases supporting a nonneoplastic eczematous diseaseJournal of the American Academy of Dermatology, 2019
- Clear cell acanthoma with changes of eccrine syringofibroadenoma: reactive change or clue to etiology?Journal of Cutaneous Pathology, 2013
- Clear-Cell Acanthoma Versus Acanthosis: A Psoriasiform Reaction Pattern Lacking Tricholemmal DifferentiationThe American Journal of Dermatopathology, 2007
- Immunohistochemical characterization of keratin expression in clear cell acanthomaBritish Journal of Dermatology, 1995
- Two cases of clear cell acanthoma: an immunohistochemical studyJournal of Cutaneous Pathology, 1988